IL6 and neoplasm: Moreover, the tumor area was also significantly larger in the combined Bev and anti-IL-6-treated group than in the groups treated with Bev alone (p = 0.002) (Fig. 2B), suggesting that IL-6 blockade disrupted both the anti-angiogenic and concomitant anti-tumor effects of Bev.